Serum levels of VEGF and MCSF in HER2+ / HER2- breast cancer patients with metronomic neoadjuvant chemotherapy

• DOI: 10.1186/s40364-018-0135-x
• Publication Date: 2018-06-13T20:10:28Z
• Authors: Roberto J. Arai; Vanessa Petry; Paulo M. Hoff; Max S. Mano
• Keywords: Neoadjuvant Therapy

Metronomic therapy has been gaining importance in the neoadjuvant setting of breast cancer treatment. Its clinical benefits may involve antiangiogenic machinery. Cancer cells induce angiogenesis to support tumor growth by secreting factors, such as vascular endothelial factor (VEGF). In cancer, Trastuzumab (TZM) based treatment is key and believed reduce diameter volume blood vessels well permeability. Here we investigated serum levels angiogenic factors VEGF MCSF patients receiving metronomic with or without TZM. We observed HER2+ cohort stable through treatment, whereas trend was decreasing levels. HER2- increasing trend. Overall, had better pathological response These findings suggest that pathway be involved TZM anti-tumoral effect setting.